Demographic and clinical outcome data for 188 patients
Demographic variable . | Value . |
|---|---|
| Age, y | |
| Average | 57 ± 16.56 |
| Median | 60 |
| Minimum | 18 |
| Maximum | 86 |
| FAB | |
| MO | 7% |
| M1 | 14% |
| M2 | 29% |
| M3 | 2% |
| M4 | 27% |
| M5 | 11% |
| M6 | 2% |
| M7 | 2% |
| Unknown | 6% |
| Cytogenetics | |
| Favorable | 11% |
| Intermediate | 48% |
| Unfavorable | 41% |
| AHD more than 2 mo | 29% |
| Etiology | |
| De novo | 68% |
| MDS evolution | 12% |
| TX-related | 20% |
| Zubrod Ps = 3 or 4 | 7% |
| Response | |
| CR | 54% |
| Failure | 12% |
| Resistant | 34% |
| Relapse | 57% |
| Median CR duration, wk | 47 |
| Median survival, wk | 42 |
| Alive | 32% |
| Med follow-up, wk | 123 |
Demographic variable . | Value . |
|---|---|
| Age, y | |
| Average | 57 ± 16.56 |
| Median | 60 |
| Minimum | 18 |
| Maximum | 86 |
| FAB | |
| MO | 7% |
| M1 | 14% |
| M2 | 29% |
| M3 | 2% |
| M4 | 27% |
| M5 | 11% |
| M6 | 2% |
| M7 | 2% |
| Unknown | 6% |
| Cytogenetics | |
| Favorable | 11% |
| Intermediate | 48% |
| Unfavorable | 41% |
| AHD more than 2 mo | 29% |
| Etiology | |
| De novo | 68% |
| MDS evolution | 12% |
| TX-related | 20% |
| Zubrod Ps = 3 or 4 | 7% |
| Response | |
| CR | 54% |
| Failure | 12% |
| Resistant | 34% |
| Relapse | 57% |
| Median CR duration, wk | 47 |
| Median survival, wk | 42 |
| Alive | 32% |
| Med follow-up, wk | 123 |
Men accounted for 50.5% of the patients.